ATS Swings to C$5.0M Q2 Loss, Scraps FY27 Growth and Margin Targets on Tariff Delays
ATS is trading near its 52-week low of $17.15 (11% above the low).
Summary
ATS posted a C$5.0M net loss on 8.6% lower revenue and withdrew its fiscal 2027 growth and margin targets, blaming tariff-driven delays in non-life sciences orders; bookings rose 12.7% to C$827M and Q3 revenue is guided to C$640M-C$680M.
Key Events · Earnings and Guidance · ATS
-
Q2 Loss as Revenue Falls 8.6%
Revenue was C$665.8M versus C$728.5M a year ago and net income swung to a C$5.0M loss (5 cents per share) from C$33.6M of income (34 cents); adjusted EBITDA fell 22.2% to C$80.7M.
-
FY2027 Targets Withdrawn
Management no longer expects modest revenue growth or 50-75 bps of margin expansion in fiscal 2027, citing delayed non-life sciences bookings and backlog conversion timing; Q3 revenue is guided to C$640M-C$680M.
-
Tariffs Hit Packaging Orders
Section 338 tariffs effective late August 2026 on Canadian-made packaging equipment sold into the U.S. worsened customer deferrals; the late-October U.S. modification eliminates the impact on a majority of covered products.
-
Bookings Up 12.7% to C$827M
Order bookings rose to C$827M from C$734M, with the highest life sciences quarterly total since Q2 FY2025 and a trailing-twelve-month book-to-bill of about 1.05:1; backlog was C$2,009M, down 2.9%.
Analysis · ATS · Technology
ATS flipped from C$33.6M of net income a year ago to a C$5.0M net loss as revenue fell 8.6% to C$665.8M, and management formally abandoned its fiscal 2027 goals of modest revenue growth and 50-75 bps of margin expansion. The culprit is a timing shift in non-life sciences orders — packaging automation in particular — made worse by Section 338 tariffs that hit Canadian-made equipment sold into the U.S. from late August. The offsetting positives are real: order bookings rose 12.7% to C$827M on record life sciences backlog, and the late-October tariff modification removes the impact on most covered products. But the near-term math is ugly — Q3 revenue is guided to C$640M-C$680M, below the current run rate, and net debt at 3.1x pro forma adjusted EBITDA sits above the 2.0-3.0x target after C$61.3M of buybacks. The C$65M-C$75M Fixed Cost Transformation savings are the main lever to rebuild margin toward the 15% long-term target.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ATS was trading at $18.96 on NYSE in the Technology sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $17.15 to $35.82. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.